In other hematological malignancies, tucidinostat inhibits MYC and BCL2 in acute myeloid leukemia [23, 24], and tucidinostat also downregulates BCL2 in combination with doxorubicin in peripheral T-cell lymphoma [25]. Here, MYC is linked to hematologic disorder.